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Abstract
Background: Recent studies have shown similarities between schizophrenia and bipolar disorder
in phenotypes and in genotypes, and those studies have contributed to an ongoing re-evaluation of
the traditional dichotomy between schizophrenia and bipolar disorder. Bipolar disorder with
psychotic features may be closely related to schizophrenia and therefore, psychosis may be an
alternative phenotype compared to the traditional diagnosis categories.
Methods: We performed a cross-study analysis of 7 gene expression microarrays that include
both psychosis and non-psychosis subjects. These studies include over 400 microarray samples
(163 individual subjects) on 3 different Affymetrix microarray platforms.
Results: We found that 110 transcripts are differentially regulated (p < 0.001) in psychosis after
adjusting for confounding variables with a multiple regression model. Using a quantitative PCR, we
validated a set of genes such as up-regulated metallothioneins (MT1E, MT1F, MT1H, MT1K, MT1X,
MT2A and MT3) and down-regulated neuropeptides (SST, TAC1 and NPY) in the dorsolateral
prefrontal cortex of psychosis patients.
Conclusion:  This study demonstrates the advantages of cross-study analysis in detecting
consensus changes in gene expression across multiple microarray studies. Differential gene
expression between individuals with and without psychosis suggests that psychosis may be a useful
phenotypic variable to complement the traditional diagnosis categories.
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Background
Kraepelin's 1896 dichotomous classification of functional
psychoses into dementia praecox (schizophrenia) and
manic-depressive insanity (bipolar disorder) is well
known and has dominated most diagnostic systems in
psychiatry. Less well known is the fact that two decades
later, Kraepelin himself questioned the validity of his clas-
sificatory system, noting that "it is becoming increasingly
clear that we cannot distinguish satisfactorily between
these two illnesses and this brings home the suspicion
that our formulation of the problem may be incorrect."
[1,2] In recent years, increasing number of observers have
shared Kraepelin's doubts, with some proposing instead a
continuum hypothesis [3,4]. Clinically, there is much
overlap of symptoms, and the intermediate category of
schizoaffective disorder may imply an artificial preserva-
tion of the dichotomy between these two diagnoses [5].
The clinical gulf between individuals with bipolar II and
those with bipolar I with psychotic features is marked,
whereas the latter often resemble individuals with schizo-
phrenia quite closely. Epidemiologically, there is also
some overlap, especially in so far as both have a winter-
spring seasonal birth excess [6,7].
Genetically, it has been said that "accumulating evidence
supports the existence of an overlap in genetic susceptibil-
ity across the traditional Kraepelinian divide" [8]; this has
been reported for family studies, linkage studies, and can-
didate genes such as G72, NRG1, dysbindin, COMT,
BDNF, and DISC1 [9-12]. An overlap for some neuropsy-
chological dysfunctions, such as working memory [13],
has also been reported, although individuals with bipolar
disorder are less severely impaired [14]. This suggests that
working memory dysfunction may be closely related to
psychotic features in individuals with schizophrenia and
with bipolar disorder.
Neuropathologically, an overlap in findings between
schizophrenia and bipolar disorder has also been noted,
both neurochemically [15] and structurally [16]. As was
true for the neuropsychology findings, individuals with
bipolar disorder are structurally less severely impaired.
Neuropathological studies that have divided bipolar
patients into those with and without psychotic features
have reported that the former are more closely related to
schizophrenia than the latter [17]. This last observation
suggests that an important variable in categorizing seri-
ously mentally ill individuals may be the presence or
absence of psychotic features. To date, most studies of
gene expression in schizophrenia and bipolar disorder
have used the traditional Kraepelinian classification. We,
therefore, decided to reanalyze a set of microarray studies,
dividing the individuals within each study into those with
and without psychotic features.
Although genome-wide expression studies of psychiatric
disorders have been published, there have been inconsist-
ent findings among previous studies possibly due to sev-
eral factors including: relatively small sample sizes,
inappropriate p-value and fold change criteria, and failure
to adjust for potential confounding variables. In order to
address these issues, we performed a cross-study analysis
of 7 microarray datasets using the subjects with and with-
out psychotic features from the two post-mortem brain
collections of the Stanley Medical Research Institute
(SMRI). The microarray datasets of the prefrontal cortex
with three Affymetrix platforms (hgu133A, hgu133 2.0+
and hgu95Av2) were used for this cross-study analysis.
Methods
Post-mortem brain tissues
Two post-mortem brain collections from the SMRI have
been made available to researchers worldwide. The first,
the Neuropathology Consortium, has 60 individual sub-
jects, with multiple brain regions per subject. The details
of the sample collection have been described previously
[18]. Notable exclusion criteria include: age>65 years,
poor quality mRNA, and significant structural brain
pathology on post-mortem examination. These samples
are matched for age, gender, race, pH, post-mortem inter-
val (PMI), side of the brain and mRNA quality. For micro-
array studies using this collection, tissue samples from the
prefrontal cortex (Brodmann area 46/10, 6 and 8/9) were
provided to individual investigators, who then performed
the RNA extraction and experiment.
The second, the Array Collection, consists of 105 individ-
ual subjects, with multiple brain regions per subject.
Exclusion criteria are similar to those for the Neuropathol-
ogy Consortium. For this collection, dorsolateral prefron-
tal cortex (Brodmann area 46) was used for the
microarrays. In contrast to the Neuropathology Consor-
tium, the SMRI performed the RNA extraction for the
Array Collection tissues. Briefly, tissue was homogenized
in Trizol; nucleic acid was separated with chloroform at
high speed centrifugation; and RNA was then precipitated
with isopropyl alcohol and washed with 70% alcohol.
Pellets of RNA were resuspended in DEPC water. The
quality of RNA was assessed using an Agilent bioanalyzer
2100 (Agilent, Foster City, CA). RNA processing and
microarray data generation was performed by the individ-
ual investigators at their own facilities. RNA processing
protocols were generally those recommended by the
Affymetrix microarray manufacturer.
For the current analysis, the subjects in the Neuropathol-
ogy Consortium and the Array Collection were divided
into two groups. Those with psychosis (N = 81) included
those with schizophrenia and those with bipolar disorder
with psychotic features. The non-psychotic controls (N =BMC Psychiatry 2008, 8:87 http://www.biomedcentral.com/1471-244X/8/87
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82) included those with bipolar without psychotic fea-
tures, those with depression, and the unaffected controls.
Two cases with bipolar disorder were excluded due to
insufficient information on psychotic features.
Quality control of microarray data
All microarray raw data (cel files) were transformed using
the Robust Multichip Average (RMA) normalization algo-
rithm. The importance of quality control (QC) measures
in microarray studies, including pre-chip (RNA quality of
samples) and post-chip outcomes of the data, has been
described previously [19]. We have performed a series of
QC analyses to identify and remove microarray chip out-
liers before conducting statistical analysis on individual
studies and on combined studies. Detailed QC procedures
are described in our previous publications [20,21]. Briefly,
each microarray chip was subjected to Affymetrix QC met-
rics for chip-level parameters such as scale factor, probe
perfect match/mismatch difference counts, percent
present calls, control gene (GAPDH and beta-actin) 5'/3'
ratios and average correlation with respect to the reference
distribution for those parameters across the arrays.
Although no hard cutoffs were applied for each of the QC
metrics, we examined the distribution of the metrics to
determine whether samples appeared to be outliers.
Analysis of microarray studies
The cross-study analysis includes 7 Affymetrix microarrays
that were completed and provided to the SMRI from each
investigator. The studies were coded as 1, 2, 3, 4, 5, 7 and
14 for the purpose of cross-study analysis to focus on the
overall results and findings of the larger investigation, and
also for the consistency with the SMRI online genomics
database http://www.stanleygenomics.org. Names of the
investigators involved in microarray studies are as follows:
Study 1: Altar A, Study 2: Altar C, Study 3: Bahn, Study 4:
Chen, Study 5: Dobrin, Study 7: Kato, Study 14: Sklar A.
It is important to note that studies based on a common
brain collection will have overlap in terms of subjects,
thus the combined analysis on these studies are not com-
pletely independent. As a result, the degrees of freedom
(df) can be over-estimated and the resulting p-values may
be insufficiently stringent. In order to adjust for this lack
of independence, a permutation method was used to
identify a correction factor that adjusts the naïve df for the
calculated p-value to a lower value (and subsequently
higher p-value) at the point where the percentage of dif-
ferentially expressed genes is equal to the selected alpha
level (i.e. 5% differentially expressed genes found at p <
0.05) based on random data. This method used 7 micro-
array studies where both individual and cross-study anal-
yses were computed for each iteration, for 100 total
iterations, similar to our previous study [21].
For each iteration, the columns of each of 7 microarray
data matrices were randomly shuffled to remove class
memberships. Then, both individual study and cross-
study analyses were computed on these permuted studies.
Next, we calculated the cross-study p-values for the genes
using df correction factor values starting at 0 and going up
to 8 by increments of 0.2. For example, if the naïve df for
gene X is 5, then using a correction value of 1.2, the
adjusted df would be 3.8 and the adjusted p-value is cal-
culated using this adjusted df. The number of genes at p <
0.05 was summated using each incremental df correction
factor for 100 total permutations and the df (based on the
naïve df minus the correction factor) that provided a
median of 5% of the genes (p < 0.05) was selected. Genes
where the difference between the naïve df and the correc-
tion factor was less than or equal to 0 were not counted in
the gene percentages. This selected correction factor was
then applied to the naïve df for each gene in the original
data to provide adjusted p-values for each gene. We
acknowledge the dependency between these studies
where certain subjects are shared; however, after correct-
ing for this over-estimated df, we found that our results
are more powered to demonstrate consensus fold changes
as compared to a single study.
Individual study analysis
First, each demographic and clinical variable was assessed
using a multiple regression model within each study. We
identified probe sets that were significantly correlated
with individual variables, where significance was defined
as p < 0.01 and fold change >1.3 (the criteria that widely
used in the previous brain microarray studies). For com-
parison of effect sizes, all demographics were analyzed
using two levels. Continuous variables and ordered cate-
gorical variables were cut at values as close as possible to
the median (e.g. continuous: PMI>30 vs. PMI<30; cate-
gorical: Heavy drug use vs. All lower levels of drug use) for
the regression analysis. Demographic variables were
assessed using both non-psychotic controls and psychosis
subjects, while disease-specific variables were analyzed
within the disease group to avoid the confounding of
demographic effects and disease effects.
The following demographic variables were considered for
all subjects: age, gender, PMI, brain pH, side of the brain,
smoking at time of death, and sudden death. For subjects
with psychosis, the following variables were considered:
disease severity, heavy alcohol use, heavy drug use, suicide
status, antipsychotic use, antidepressant use, and mood
stabilizer use. Following the demographic analyses, the
psychosis class was analyzed to identify a list of discrimi-
nating genes adjusted for the demographic terms (we used
a common set of demographics for all analyses, including
brain pH, PMI, lifetime antipsychotics, bipolar disorder,
mood stabilizer lithium, lifetime alcohol, lifetime drug)BMC Psychiatry 2008, 8:87 http://www.biomedcentral.com/1471-244X/8/87
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or markers indicative of disease between the psychosis
subjects and non-psychotic controls. The multiple regres-
sion analysis provided an adjusted fold change, standard
error (SE), and p-value for each gene in each study.
Cross-study analysis
The cross-study comparisons are based on scaled repre-
sentations of individual study-level analysis across studies
to extract the biological patterns and relationships. For the
gene level analysis, consensus fold change was calculated
for each gene based on a weighted combination of the
individual fold changes and the SEs for the Affymetrix
probe sets that map to each gene across the studies.
Weights were determined in a probe set specific manner to
account for the different levels of precision associated
with each probe set that map to a given gene across the
platforms. The weights were equal to 1/SEi, where SEi is
the standard error of the ith probe set for the gene across
all the studies. For the Gene Ontology (GO) analysis, GO
association to disease was tested using a Fisher's Exact test
(p < 0.05), based on the number of significantly regulated
genes from the cross-study analysis within each GO term.
Each GO term with number of genes between 10 and 500
were retained in the cross-study analysis. Additional infor-
mation about cross-study analysis can be found at the
SMRI online genomics database http://www.stanleygen
omics.org/cross.html. The false discovery rate (FDR) was
calculated based on the ratio of expected number of genes
by chance at the specific p-value threshold (e.g. at p =
0.0001 and 19,502 genes = expect 2 genes by chance)
divided by the sum of the expected number of genes by
chance and the actual number of genes obtained at that
threshold.
Bioinformatics mappings
NCBI's Database for Annotation, Visualization and Inte-
grated Discovery (DAVID 2007) was used as the standard
source for gene annotation information [22]. The primary
fields extracted from the DAVID include: Entrez ID, gene
symbol, gene name and gene summary. Additional anno-
tations include gene product mappings to the GO Consor-
tium for the GO terms/classes. For microarrays, queries
were based on the Affymetrix probe set ID (AFFYID).
Real-time quantitative PCR
Total RNA was extracted from the dorsolateral prefrontal
cortex tissues (BA46) of the Array Collection (psychosis N
= 56, non-psychosis N = 49). RNA was further purified
with the PureLink Micro to Midi Total RNA Purification
System (Invitrogen, Carlsbad, CA) and the quality of RNA
was assessed with the Bioanalyzer 2100 (Agilent, Foster
City, CA). cDNA was synthesized with RT-PCR using oligo
dT primers (Super Script III, Invitrogen, Carlsbad, CA).
For real-time PCR, 1 μl aliquots of validated QuantiTect
SYBR primer (Qiagen, Valencia, CA), 10 μl qPCR Master
mix (Applied Biosystems, Foster City, CA), and 10 μl
diluted cDNA were mixed together and pipetted into sin-
gle wells of the qPCR plate (384-well format) with the
Prism7900HT Sequence Detection System (Applied Bio-
systems, Foster City, CA). For no template controls for
each gene tested, water was added instead of the cDNA.
Thermo cycle conditions were: (1) 1 cycle for 2 min at
50°C, (2) 1 cycle for 15 min at 95°C, and (3) 40 cycles for
15 sec at 95°C and 1 min at 60°C and fluorescence was
measured during the 60°C step for each cycle as recom-
mended by the manufacturer. Reactions were quantified
by the delta delta cycle threshold (Ct) method using
SDS2.2 software (Applied Biosystems, Foster City, CA)
generating a mean quantity value (Qty mean) for each
sample from the triplicates of that sample for each gene.
Recent studies have shown an advantage of using multiple
endogenous control genes for the qPCR experiment [23],
and therefore we used three endogenous control genes
including  β-2 microglobulin (B2M), glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) and β-actin (ACTB)
in the qPCR experiment. The data for each gene of interest
was expressed as Qty mean for the gene of interest/geo-
metric mean of Qty mean values for the three endogenous
control genes. Normalized values were then expressed as
fold changes between the psychosis and the non-psycho-
sis control group.
Results
A summary of subject characteristics in 7 microarray stud-
ies is shown in Table 1. There were no significant differ-
ences in age, gender, race, brain pH and PMI between the
psychosis and the non-psychosis group; this is important
since these demographic and post-mortem variables
appear to influence gene expression in the post-mortem
brains. The psychosis subjects had a higher incidence of
smoking at time of death, heavy drug use, heavy alcohol
use, and suicide status compared to the non-psychosis
controls, and these factors tend to be associated with psy-
Table 1: Summary of subject characteristics in the studies 
included in the cross-study analysis of psychosis
Controls Psychosis
# of Samples (Subjects) 213 (82) 220 (81)
Age 44.7+/- 9.8 43.9 +/- 10.2
Gender 70% Male 60% Male
Race 97% White 93% White
pH 6.49 +/- .32 6.34 +/- .28
PMI 31.0 +/- 15.8 32.9 +/- 15.7
Smoking at TOD 25% 57%
Heavy Drug Use 6% 23%
Heavy Alcohol Use 11% 31%
Suicide 11% 32%
For each variable, mean ± standard error or percentage value is 
reported. PMI: post-mortem interval, TOD: time of deathBMC Psychiatry 2008, 8:87 http://www.biomedcentral.com/1471-244X/8/87
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chotic features. Therefore, these psychosis-specific varia-
bles were included in the following demographic analysis.
Table 2 represents the characteristics of individual studies,
including the number of samples, brain collection, brain
region, Affymetrix platform and number of probe sets in
each study. Four studies (Study ID 1, 3, 5 and 7) used the
Array Collection and three studies (Study ID 2, 4 and 14)
used the Neuropathology Consortium. Note that total
number of samples included in each study vary from 26 to
86. This is due to the availability of microarray raw data
from each study and also due to the removal of poor qual-
ity arrays based on the QC analysis. Removal of microar-
ray outliers was carried out before statistical analysis of
individual and combined study analyses. Nonetheless, we
validated a set of genes with the qPCR using a complete
set of dorsolateral PFC tissues (N = 105) from the Array
Collection.
As an initial comparison across individual studies prior to
the cross-study analysis, we used the significance criteria
(p < 0.01 and fold change>1.3) that had been widely used
in the previous microarray studies. The percentage of
genes regulated by individual factors within each study is
shown in Table 3. The median percentage of genes signif-
icantly regulated in psychosis is 0.62%, indicating the sec-
ond highest percentage of genes significantly regulated.
Brain pH was the most influential factor for gene expres-
sion with the median percentage of 1.28%. Other factors,
including PMI (0.13%), heavy alcohol use (0.27%),
antipsychotic use (0.28%) and lithium use (0.22%), also
showed comparable number of gene expression changes
in this analysis.
Following the analyses on individual studies, we per-
formed cross-study analysis to identify a list of discrimi-
nating genes in psychosis. Table 4 represents the summary
results of the cross-study analysis including fold changes
and p-values for all genes. Most genes showed small fold
changes (less than 1.3) in this analysis. The cumulative
FDR analysis indicates that a p-value cutoff of 0.001
would maximize the number of genes while keeping the
FDR relatively low (14%). For example, 110 genes
showed a highly significant change at p < 0.001 (see Addi-
tional file 1). The number of genes found to be differen-
tially expressed while maintaining a relatively low FDR
illustrates the robust expression differences between indi-
viduals with and without psychosis.
From the cross-study analysis, we have identified the
genes that are differentially regulated in psychosis com-
pared to non-psychosis using a relatively large fold change
and moderate p-value threshold (p < 0.05). Such guide-
lines have been suggested by the MicroArray Quality Con-
trol (MAQC) I project to maximize reproducibility of
differential expression across platforms [24]. Addition-
ally, large fold change magnitudes are preferred for valida-
tion purposes on an alternative platform such as qPCR.
Among differentially regulated genes, a set of metal-
lothionein genes are consistently up-regulated across the
studies (Figure 1). The p-values and fold changes for the
genes are MT1E (p = 0.002, FC 1.22), MT1F (p = 0.00005,
FC 1.1), MT1K (p = 0.027, FC 1.26) and MT1X (p =
0.0001, FC 1.31). As shown at the bottom of each graph,
the combined analysis with weighted fold change and
95% confidence intervals indicates significant expression
changes. For instance, MT1F gene is not significant in
most individual studies, however, the combined analysis
clearly shows that MT1F gene is significantly up-regulated
because of the increased power to detect small but consist-
ent changes across multiple studies (Figure 1B).
Down-regulated genes in psychosis include several neu-
ropeptide genes (Figure 2). The p-values and fold changes
for the genes are somatostatin (SST) (p = 0.038, FC -1.17),
Tachykinin precursor 1 (TAC1) (p = 0.04, FC -1.17), and
Table 2: Summary of the seven microarray studies included in the cross-study analysis of psychosis
Study ID Samples Controls Psychosis Collection* Region Array Type Probesets
1 81 38 43 A Frontal
BA46
Affy hgu133A 22283
2 55 30 25 C Frontal BA46/10 Affy hgu133A 22283
3 86 42 44 A Frontal
BA46
Affy hgu133A 22283
4 26 16 10 C Frontal
BA6
Affy hgu133 2.0+ 54681
5 73 35 38 A Frontal
BA46
Affy hgu133 2.0+ 54681
7 81 35 46 A Frontal
BA46
Affy hgu133A 22283
14 31 17 14 C Frontal
BA8/9
Affy Hgu95Av2 12453
*A = Array Collection, C = Neuropathology ConsortiumBMC Psychiatry 2008, 8:87 http://www.biomedcentral.com/1471-244X/8/87
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neuropeptide Y (NPY) (p = 0.05, FC -1.09). A nuclear
receptor subfamily 4, group A, member 2 (NR4A2) gene
was also down-regulated (p = 0.00001, FC -1.16) in psy-
chosis. This gene has been implicated in psychiatric disor-
ders including schizophrenia and bipolar disorder. Most
individual studies show consistent down-regulation of
NR4A2 gene, except the study 4, and the combined anal-
ysis at the bottom indicates that NR4A2 gene is signifi-
cantly down-regulated in psychosis (Figure 2D).
The GO analysis of metal ion binding function is shown
in Figure 3. The metallothionein genes including MT1E (p
= 0.002, FC 1.22), MT1F (p < 0.0001, FC 1.1), MT1H (p =
0.007, FC 1.14), MT1K (p = 0.027, FC 1.26), MT1X (p =
0.0001, FC 1.31), MT2A (p = 0.023, FC 1.16), and MT3 (p
= 0.001, FC 1.08) are constantly up-regulated as com-
pared to other genes associated with the metal ion bind-
ing function. Metal ion binding was found to be among
the top 9 GO terms significantly regulated in the cross-
study analysis of psychosis (p = 0.01) and was chosen to
highlight based on the robust and consistent changes in a
shared gene group (i.e. metallothionein genes). Addi-
tional significant GO terms include: regulation of cell
growth (p = 0.001), negative regulation of transcription
from Pol II promoter (p = 0.003), voltage-gated potas-
sium channel activity (p = 0.005), metabolism (p =
0.006), translational elongation (p = 0.006), learning
and/or memory (p = 0.006), WNT receptor signaling
pathway (p = 0.008), and glutathione transferase activity
(p = 0.009) (see Additional file 2).
Following the cross-study analysis of microarrays, we per-
formed a qPCR experiment to validate gene expression
changes that we observed in microarrays (Figure 4). We
confirmed differential expression of metallothionein
genes including MT1X (p = 0.001, FC 1.64), MT2A (p =
Table 3: Demographic and clinical variable analysis in individual studies
Factor Median % Regulated in Individual Studies
Psychosis .62%
Smoking .03%
Gender .12%
PMI .13%
Brain Side .03%
Brain pH 1.28%
Age .03%
Heavy Alcohol Use .27%
Heavy Drug Use .12%
Suicide .05%
Agonal State (Sudden Death) .19%
Antidepressant Use .04%
Antipsychotic Use .28%
Mood Stabilizer Use .09%
Lithium Use .22%
Valproate Use .07%
Median percentage of genes regulated in individual studies is shown with each variable. The criteria of significance (p-value < 0.01 and FC >1.3).
Table 4: Summary of cross-study analysis of psychosis showing fold changes and p-values.
Psychosis Combined Analysis
p-value
Fold Change <.0001 .0001–.0005 .0005–.001 .001–.005 .005–.01 .01–.05 >.05
1–1.1 28 40 26 184 197 1327 17343
1.1–1.2 5 4 3 18 14 73 192
1.2–1.3 1 0 2 2 1 5 31
>1.3 0 1 0 0 0 0 5
Total 34 45 31 204 212 1405 17570
Chance 2 7 9 72 90 725 18527
Cum total 34 79 110 314 526 1931 19502
Cum chance 2 9 18 90 180 906 19502
Cum FDR 5.6% 10.2% 14.1% 21.8% 25.5% 31.9% ---
Cum total: Cumulative total, Cum FDR: Cumulative false discovery rateBMC Psychiatry 2008, 8:87 http://www.biomedcentral.com/1471-244X/8/87
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Increased gene expression of metallothioneins in the cross-study analysis of psychosis Figure 1
Increased gene expression of metallothioneins in the cross-study analysis of psychosis. A: metallothionein 1E, B: 
metallothionein 1F, C: metallothionein 1K, D: metallothionein 1X. The plots with fold changes and 95% confidence intervals 
show consistent up-regulation of metallothioneins across individual studies as shown on the Y-axis. Combined analysis shown 
on the bottom of each panel represents the weighted fold change and 95% confidence intervals for each gene.BMC Psychiatry 2008, 8:87 http://www.biomedcentral.com/1471-244X/8/87
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0.009, FC 1.51), MT1E (p = 0.01, FC 1.47), MT1K (p =
0.005, FC 1.47), MT1H (p = 0.03, FC 1.36), MT3 (p =
0.004, FC 1.3) and MT1F (p = 0.02, FC 1.3). The order of
fold changes of metallothionein genes in the qPCR corre-
sponds to the order of fold changes of these genes
observed in the microarray analysis. We have also con-
firmed that expression of the neuropeptide genes are
down-regulated in psychosis; NPY (p = 0.02, FC -1.32),
NR4A2 (p = 0.01, FC -1.39), SST (p = 0.001, FC -1.57) and
TAC1 (p = 0.01, FC -1.6). Overall fold changes of these
Decreased gene expression of neuropeptides in the cross-study analysis of psychosis Figure 2
Decreased gene expression of neuropeptides in the cross-study analysis of psychosis. A: somatostatin, B: tachyki-
nin, precursor 1, C: neuropeptide Y, D: NR4A2. The plots with fold change and 95% confidence intervals show consistent 
down-regulation across multiple individual studies. Combined analysis shown on the bottom of each panel represents the 
weighted fold change and 95% confidence intervals for each gene.BMC Psychiatry 2008, 8:87 http://www.biomedcentral.com/1471-244X/8/87
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genes that we found with the qPCR experiment are larger
than fold changes observed in the microarray analysis.
Discussion
In the current study, we have found the genes that are dif-
ferentially regulated in the prefrontal cortex of individuals
with psychosis. These findings are important because we
performed a cross-study analysis of seven microarray stud-
ies that used three different Affymetrix platforms with two
different post-mortem brain collections. Therefore, these
gene expression changes are "consensus" fold changes
Consistent up-regulation of metallothionein genes among metal ion binding genes in the Gene Ontology (GO) term Figure 3
Consistent up-regulation of metallothionein genes among metal ion binding genes in the Gene Ontology (GO) 
term. Seven metallothionein genes including MT1E, MT1F, MT1H, MT1K, MT1X, MT2A and MT3 are significantly up-regulated 
in this category.BMC Psychiatry 2008, 8:87 http://www.biomedcentral.com/1471-244X/8/87
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Quantitative PCR validation of metallothionein and neuropeptide genes Figure 4
Quantitative PCR validation of metallothionein and neuropeptide genes. The gene plots with fold changes and 95% 
confidence intervals show that metallothionein genes including MT1X, MT2A, MT1E, MT1K, MT1H, MT3, AND MT1F are sig-
nificantly up-regulated and four genes including NPY, NR4A2, SST and TAC1 are significantly down-regulated in psychosis (p < 
0.05).BMC Psychiatry 2008, 8:87 http://www.biomedcentral.com/1471-244X/8/87
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across multiple microarray studies following adjustment
of confounding variables in individual studies.
It is well known that gene expression studies of psychiatric
disorders using post-mortem brains are more challenging
than others [25-28]. Possible reasons for this complexity
include pre- and post-mortem factors such as RNA qual-
ity, brain pH, PMI and agonal state that affect gene expres-
sion patterns in the brains of psychiatric patients [23].
Moreover, biological and disease-specific effects are often
hindered by several issues such as relatively small sample
sizes, small effect sizes and heterogeneity of psychiatric
phenotypes in the general population. The clinical infor-
mation available for the patients is typically sparse, so that
unknown clinical covariates may either confound or con-
fuse many of the gene expression findings in psychiatric
disorders [20]. Therefore, appropriate statistical adjust-
ment using such demographic and clinical information is
critical in order to improve inferences in determining
putative genes and biological pathways in psychiatric dis-
orders.
Gene expression microarray technology has become a
powerful tool for discovery, although this technology had
some limitations such as high cost of experiments, limited
sample size, and lack of standardization on data analysis.
Recently, there have been improvements in the microar-
ray field, and more microarray datasets are available for
meta-analysis. Several studies have described important
issues related to the meta-analysis of microarray data
including standardization, statistical analysis and data-
basing strategy [29], and the development of new bioin-
formatic tools such as searchable online archives of
genetic/genomic findings in psychiatric disorders [30].
One of the main advantages of meta-analysis as compared
to an individual study is the increased statistical power to
detect consensus fold changes across multiple studies. It
has been reported that gene expression changes in post-
mortem brains of psychiatric patients are relatively small.
This may explain some of the discrepancies in previous
studies that reported putative genes in psychiatric disor-
ders, because most of the studies were not sufficiently
powered (due to small sample sizes) to detect small
changes in gene expression. Moreover, some studies did
not have sufficient clinical information of post-mortem
brains to adjust for possible confounding variables.
In the current analysis, we have included seven microarray
studies that used the frontal cortex (BA46/10, BA8/9 and
BA6) as compared to the previous study [21] that included
the cerebellum studies. A recent study demonstrated that
different brain regions such as the frontal, cingulate, tem-
poral, parietal, occipital cortices, hippocampus and sub-
cortical regions show different patterns of gene expression
[31]. The authors also found that gene expression patterns
in the prefrontal cortices (BA10 and BA46) are similar to
each other as compared to non-frontal regions. To our
knowledge, there is little evidence on gene expression dif-
ferences in the sub-regions of the frontal cortex because
most studies have focused on one region of the frontal
cortex of schizophrenia patients. Another limitation was
an availability of the prefrontal cortex (BA46) tissues from
the Neuropathology Consortium when individual micro-
array studies were conducted. This brain cohort has been
used by many investigators for various types of research in
the past. Therefore, we included 3 studies that used the
frontal cortices (BA46/10, BA8/9 and BA6) from the Neu-
ropathology Consortium because these regions are adja-
cent to each other and have been implicated in
schizophrenia [32-34]. Nevertheless, we included another
4 studies that used the Array Collection with the same dor-
solateral prefrontal cortex (BA46).
In the current cross-study analysis, we identified a set of
metallothionein genes including MT1X, MT1K, MT1E,
MT1H, MT1F, MT2A and MT3 that are significantly up-
regulated in psychosis. We used a real-time qPCR to vali-
date differential expression of metallothionein genes in
the prefrontal cortex (BA46) of psychosis patients. Real-
time qPCR is often referred as the gold standard for vali-
dation of gene expression in microarrays due to its advan-
tages in detection sensitivity, large scale dynamic range,
high precision and reproducible quantitation compared
to other techniques [35,36]. For the qPCR, we used a com-
plete set of dorsolateral prefrontal cortex (BA46) tissues
from the Array Collection (psychosis N = 56, non-psycho-
sis N = 49). It is important to note that most previous
microarray studies have used a relatively small number of
post-mortem brains for the qPCR validation.
Although metallothioneins were discovered almost 50
years ago, their functional role in the brain has not been
well-characterized. Putative physiological functions of
metallothioneins in the CNS, including neuroprotection,
regeneration and cognitive function, have been described
in a recent paper [37]. Other studies reported that metal-
lothioneins are involved in cellular host defense response,
stress response, immunoregulation, cell survival and
brain repair [38-41]. Astrocytes appear to be the main
source of metallothioneins in the brain, even though the
primary function of metallothioneins are protecting neu-
rons from a variety of pathology [42]. Increased MT1 and
MT2 gene expression have been reported in several types
of brain pathology including traumatic and excitotoxic
injury, amyotrophic lateral sclerosis, Alzheimer's disease
and Parkinson's disease [43-47]. Studies using animal
models showed that metallothioneins may be involved in
behavior associated with substance dependence [48] and
learning and memory [49]. Similar to our findings, one
study reported that MT2A gene expression is increased inBMC Psychiatry 2008, 8:87 http://www.biomedcentral.com/1471-244X/8/87
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the PFC of schizophrenia patients [50]. These results sug-
gest that metallothioneins in the brain may play a signifi-
cant role in neuroprotection and cognitive function. It is
possible that neurodegenerative process may disrupt cog-
nitive function in the frontal cortex of psychosis patients
and up-regulation of metallothionein genes in the PFC
may be a compensatory mechanism against these adverse
processes. Interestingly, a recent study reported that met-
allothionein-related compounds are well tolerated in ani-
mal studies [39], and therefore, these compounds may be
potential candidates for novel medication development
in psychosis-related disorders.
The genes down-regulated in psychosis include neuropep-
tide genes such as somatostatin (SST), neuropeptide Y
(NPY) and tachykinin (TAC1). The neuropeptide genes
have been implicated in working memory function and in
schizophrenia [51]. The NPY gene may be associated with
schizophrenia [52], impulsivity [53], aggression and
bipolar disorders [54,55]. Previous studies reported
decreased NPY levels in the temporal cortex of schizo-
phrenia [56] and decreased NPY receptor gene expression
in lymphocytes of schizophrenia [57]. Gabriel et al
reported that both NPY and SST levels are decreased in the
cerebral cortex of individuals with schizophrenia [58]. A
microarray study reported that SST gene expression is
increased in the PFC of bipolar disorder but not with
schizophrenia patients [59]. It is possible that this study
may not have been sufficiently powered (due to small
sample sizes) to detect small gene expression changes in
schizophrenia. Consistent to the current results, mRNA
levels of SST in the PFC are decreased in schizophrenia
patients in a study using in situ hybridization [60] and
another microarray study reported that both SST and NPY
expression levels are decreased in the PFC of schizophre-
nia [51]. TAC1-related genes are also implicated in psychi-
atric disorders [61,62] and increased protein levels of
TAC1 receptor in the PFC of schizophrenia have been
reported [63]. Taken together, previous findings and the
current results provide strong evidence for involvement of
neuropeptide genes in psychosis-related disorders.
One of the potential confounding variables affecting neu-
ropeptide gene expression may be the antipsychotic med-
ication. Previous studies reported that NPY levels in the
brain are affected by various drugs including typical and
atypical antipsychotics [64,65]. Using rodents, one study
reported that NPY and SST levels are increased in the PFC
following haloperidol treatment [66], while another
study reported that NPY levels are decreased following
chronic antipsychotic treatment [67]. However, GABA-
system related genes including SST are not changed in the
PFC of monkey brains treated with chronic antipsychotic
drugs [51]. In order to minimize the confounding effect of
antipsychotic medication from the disease effect, we used
multiple regression models to adjust antipsychotic medi-
cation in the current analysis.
Another gene down-regulated in psychosis is the tran-
scription factor Nurr1 (NR4A2), an orphan nuclear recep-
tor associated with the development of dopaminergic cells
in the mid-brain (p < 0.00001, FC-1.16). This gene has
been implicated in attention deficit hyperactivity disor-
der, alcohol dependence, schizophrenia and bipolar dis-
order [68-70]. A recent study with NR4A2 knock-out mice
suggests that these animals display behavioral endophe-
notypes that are displayed in other animal models of psy-
chosis/schizophrenia. [71]. Therefore, reduced NR4A2
gene expression in the PFC may be associated with psy-
chotic features.
Although genome-wide gene expression profiling in the
postmortem brains may reveal valuable information
related to psychiatric disorders, this approach alone is
limited in terms of being able to distinguish between
changes reflecting the primary disease etiology from those
reflecting compensatory mechanisms and many potential
confounding influences such as medications and drug use
[72]. Therefore, it is necessary to study the relationship
between gene expression, genetic and epigenetic varia-
tions in individuals with psychiatric disorders. The inte-
gration of postmortem gene expression with genetic
variations including single nucleotide polymorphisms
(SNPs) is the subject of ongoing investigations.
Conclusion
We found a set of genes that are differentially regulated in
the prefrontal cortex of individuals with psychosis.
Among those genes, metallothionein genes are consist-
ently up-regulated and neuropeptide genes are down-reg-
ulated. These genes may have implications in
neurodegeneration and working memory function in the
prefrontal cortex that are thought to be disrupted in psy-
chosis. With an advantage of cross-study analysis, we were
able to detect small but "consensus" changes in gene
expression across multiple microarray studies. By combin-
ing gene expression analyses across multiple microarray
studies and with the qPCR validation of putative genes,
we can provide greater confidence in the scientific find-
ings, which include potential genes and biological path-
ways in psychiatric disorders, as compared to the result
obtained from a single study.
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